Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Short-term Investments (2020 - 2025)

Arcutis Biotherapeutics has reported Short-term Investments over the past 6 years, most recently at $178.1 million for Q4 2025.

  • Quarterly results put Short-term Investments at $178.1 million for Q4 2025, up 13.7% from a year ago — trailing twelve months through Dec 2025 was $178.1 million (up 13.7% YoY), and the annual figure for FY2025 was $178.1 million, up 13.7%.
  • Short-term Investments for Q4 2025 was $178.1 million at Arcutis Biotherapeutics, up from $143.9 million in the prior quarter.
  • Over the last five years, Short-term Investments for ARQT hit a ceiling of $395.4 million in Q3 2022 and a floor of $118.1 million in Q2 2025.
  • Median Short-term Investments over the past 5 years was $204.7 million (2024), compared with a mean of $223.8 million.
  • Biggest five-year swings in Short-term Investments: skyrocketed 510.8% in 2021 and later crashed 69.74% in 2023.
  • Arcutis Biotherapeutics' Short-term Investments stood at $290.6 million in 2021, then rose by 22.48% to $355.9 million in 2022, then plummeted by 48.46% to $183.5 million in 2023, then dropped by 14.63% to $156.6 million in 2024, then increased by 13.7% to $178.1 million in 2025.
  • The last three reported values for Short-term Investments were $178.1 million (Q4 2025), $143.9 million (Q3 2025), and $118.1 million (Q2 2025) per Business Quant data.